logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
高

高强 (Qiang Gao)

fudan university
H指数:74
被引数:2.0万

个人简介

医学博士，教授，博士生导师，主任医师，复旦大学附属中山医院（2020.12-至今），特聘教授（2019.11-至今），研究员（破格）（2016.12-至今），副主任医师（2015.12-至今），主治医师（2009.7-2015.11），住院医师（2008.7-2009.06）。教育经历：硕博连读复旦大学附属中山医院（2003.9-2008.7），学士蚌埠医学院临床医学系（1998.9-2003.7）。获国家优秀青年科学基金(2016)、上海市优秀学科带头人(2017)、上海市优秀学术带头人(2019)、上海市“曙光计划”（2017）、上海市优秀青年医学人才(2013)、上海市“青年科技启明星计划”（2010）。获教育部青年科学奖（2017）、教育部自然科学一等奖（2016）、上海市科技创新“市长奖”（2015）、树兰医学青年奖（2015）、吴孟超医学青年奖（2013）、上海市“银蛇奖”二等奖（2013）、卫生系统“全国青年岗位能手”（2012）、复旦大学“十大医务青年”（2011）、全国优秀博士学位论文（2010）、复旦大学“校长奖”（2008）。

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

中国患者术后肝内胆管癌的辅助性卡瑞利珠单抗联合卡培他滨治疗（ACC）：一项单臂、单中心、开放标签、II期临床试验

The Lancet Gastroenterology & Hepatology
IF38.6
2025-11-270
PRE
Zheng Wang; Lixing Li; Peiran Huang; Honghu Tu; Xiangyu Zhang; Lei Yu; Fei Liang; Cheng Huang; Shuangjian Qiu; Qinghai Ye; Zhenbin Ding; Xiaowu Huang; Yinghong Shi; Kang Song; Huichuan Sun; Xiaoying Wang; Yongfeng Xu; Yao Yu; Qiang Gao; Lan Zhang
PTPN9 dephosphorylates IGF1RY1165/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma

PTPN9去磷酸化IGF1RY1165/1166，并缓解胆管癌中IGF1R介导的对酪氨酸激酶抑制剂的耐药性。

Journal of Experimental & Clinical Cancer Research
IF12.8
2025-11-230
OA
Jia-ming Hu; Hui-qiang Liu; Ming-hui Zhang; Tian-li Chen; An-da Shi; Qiang Gao; Yun-jia Liu; Xin Wang; Kai-yang Sun; Jian Deng; Yun-fei Xu; Chang Pan; Kang-shuai Li; Zong-li Zhang
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

替雷利珠单抗联合仑伐替尼和GEMOX方案治疗不可切除的局部晚期胆道癌的转化治疗（ZSAB-TransGOLP）：一项多中心、前瞻性、Ⅱ期研究

The Lancet Oncology
IF0
2025-08-290
PRE
Guoming Shi; Xiaoyong Huang; Xiaowu Li; Fei Liang; Qiang Gao; Daohan Zhang; Jiacheng Lu; Yuan Ji; Zhiqiang Hu; Yi Chen; Shuangjian Qiu; Yong Yi; Xiaodong Zhu; Huichuan Sun; Yinghong Shi; MinJie Peng; Xiaoying Wang; Cheng Huang; Zhenbin Ding; Yifeng He; Yinghao Shen; Yongfeng Xu; Yongsheng Xiao; Jie Hu; Jian Zhou; Jia Fan
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study

一线tislelizumab和ociperlimab联合吉西他滨和顺铂治疗晚期胆道癌 (zsab-top): 一项多中心，单臂，2期研究

Signal Transduction and Targeted Therapy
IF52.7
2025-08-210
OAAI
Guoming Shi; Xiaoyong Huang; Liang Ma; Hui Li; Jianhong Zhong; Junye Wang; Qiang Gao; Xiaojun Guo; Shuangjian Qiu; Huichuan Sun; Yinghong Shi; Xiaowu Huang; Xiaoying Wang; Yong Yi; Xiaodong Zhu; Cheng Huang; Zhenbin Ding; Yi Chen; Yifeng He; Yinghao Shen; Qiman Sun; Jian Zhou; Jia Fan
From complexity to consensus: A roadmap for neutrophil classification

从复杂性到共识：中性粒细胞分类的道路图

Immunity
IF26.3
2025-08-040
PRE
Lai Guan Ng; Ivan Ballesteros; Marco A. Cassatella; Mikala Egeblad; Zvi G. Fridlender; Dmitry Gabrilovich; Qiang Gao; Zvi Granot; Ricardo Grieshaber-Bouyer; H. Leighton Grimes; Catherine C. Hedrick; Andrés Hidalgo; Mariana J. Kaplan; Paul Kubes; Guang Sheng Ling; Liming Lu; Hongbo R. Luo; Tanya N. Mayadas; Niki M. Moutsopoulos; Melissa Ng; Peter A. Nigrovic; Renato Ostuni; Mikael J. Pittet; Daniela F. Quail; Carlos Silvestre-Roig; Oliver Soehnlein; Irina A. Udalova; Ruidong Xue; Ning Zhang; Immanuel Kwok
The coming era of proteomics-driven precision medicine

蛋白质组学驱动的精准医学时代即将到来。

NATIONAL SCIENCE REVIEW
IF17.1
2025-08-014
OAAI
Jiang, Ying; Wang, Jian; Sun, Aihua; Zhang, Hongxing; Yu, Xiaobo; Qin, Weijie; Ying, Wantao; Li, Yanchang; Chang, Cheng; Wang, Xiaowen; Xie, Linhai; Liu, Wei; Liu, Jialin; Zhang, Xiaomei; Yan, Qunjiao; Zou, Yu; Zhao, Chuanping; Sun, Haofan; Zhang, Jian; Su, Shicheng; Gao, Qiang; He, Fuchu
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

《柳叶刀》关于应对全球肝细胞癌负担的委员会报告：从预防到治疗的综合策略

lancet
IF0
2025-07-280
PRE
Stephen Lam Chan; Hui-Chuan Sun; Yang Xu; Hongmei Zeng; Hashem B El-Serag; Jeong Min Lee; Myron E Schwartz; Richard S Finn; Jinsil Seong; Xin Wei Wang; Valérie Paradis; Ghassan K Abou-Alfa; Lorenza Rimassa; Jia-Horng Kao; Bo-Heng Zhang; Josep M Llovet; Jordi Bruix; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Landon L Chan; Man-Qi Liu; Qiang Gao; Feng Shen; Robin Kate Kelley; Ann-Lii Cheng; Masayuki Kurosaki; Hidenori Toyoda; Wei-Xia Chen; Takamichi Murakami; Ping Liang; Jessica Zucman-Rossi; Yasunori Minami; Shiro Miyayama; Kui Wang; Kwan Man; Kiyoshi Hasegawa; Qiu Li; Kaoru Tsuchiya; Li Xu; Valerie Chew; Pierce Chow; Yujin Hoshida; Amaia Lujambio; Irene Oi-Lin Ng; Michiie Sakamoto; Young Nyun Park; Thomas Yau; Masatoshi Kudo; Jia Fan; Jian Zhou
A noninvasive and highly efficient epigenetic predictive model for efficacy of the GOLP regimen in patients with intrahepatic cholangiocarcinoma

一种非侵入性且高效的原癌基因表观遗传预测模型，用于预测GOLP方案在内脏肝内胆管癌患者中的疗效

Cancer Letters
IF10.1
2025-07-100
OA
Xianlong Meng; Jiacheng Lu; Xiaoyong Huang; Yixiang Shi; Lei Yu; Xiaojun Guo; Pei Pu; Zhiqiang Hu; Shuyang Hu; Mu Ye; Xiaolong Cui; Chen Liang; Jiabin Cai; Qiman Sun; Yinghao Shen; Qiang Gao; Xiaolan Wang; Chuan He; Jian Zhou; Jia Fan; Guoming Shi
2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione from Averrhoa carambola L. roots: Suppressing hepatocellular carcinoma progression through ROS accumulation and p53 pathway-mediated apoptosis

2-十二烷基-6-甲氧基环己二烯-2,5-二酮-1,4-二酮来自Averrhoa carambola L.根：通过ROS积累和p53通路介导的凋亡抑制肝癌进展

TOXICOLOGY AND APPLIED PHARMACOLOGY
IF3.4
2025-05-010
PRE
Chen, Meifeng; Pang, Hongbing; Pham, Thi Thai Hoa; He, Yongfei; Gao, Qiang; Liao, Yuan; Zhu, Chunyi; Chen, Linqian; Yan, Guohong; Mo, Shutian; Han, Chuangye

研究方向

肿瘤异质性和个体化治疗
樊
樊嘉
H 指数:126论文数:1,505被引数:6.8万
周
周箭
H 指数:104论文数:1,031被引数:4.6万
X
Xiaoying Wang
H 指数:42论文数:137被引数:8,897
J
Jian Zhou
H 指数:59论文数:474被引数:1.4万
A
Ai‐Wu Ke
H 指数:53论文数:185被引数:1.0万
Z
Zhen‐Bin Ding
H 指数:43论文数:190被引数:6,199
曹
曹亚
H 指数:70论文数:480被引数:1.8万
L
Liangqing Dong
H 指数:20论文数:90被引数:3,328
S
Shuang–Jian Qiu
H 指数:55论文数:274被引数:1.1万
J
Jie-Yi Shi
H 指数:25论文数:87被引数:2,715